Nuvation Bio Inc (NUVB) has disclosed a new risk, in the Sales & Marketing category.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nuvation Bio Inc. faces a significant business risk in its efforts to commercialize taletrectinib outside the U.S. and its partnered territories. The company has out-licensed rights in certain Asian regions but must decide whether to establish its own sales infrastructure or partner with third parties in other jurisdictions. Both strategies carry inherent risks, such as the high costs and potential delays of building a sales force or the lower profitability and dependency on third-party efforts. Failure to effectively establish sales and marketing capabilities could hinder the successful commercialization of taletrectinib and other product candidates.
Overall, Wall Street has a Strong Buy consensus rating on NUVB stock based on 8 Buys.
To learn more about Nuvation Bio Inc’s risk factors, click here.